Evonetix extends Series B financing to US$54m
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Germanys Curevac offers common shares
/in News/by Thomas GabrielczykmRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Chong Kun Dang Pharm licences Synaffix ADC platform
/in News/by Thomas GabrielczykSouth Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BVs propietary ADC platform.
New EU stakeholder platform to speed up clinical trials
/in News/by Thomas GabrielczykA new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Ultra-processed foods increase risk for cancer
/in News/by Thomas GabrielczykBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Evotec and Janssen team up in immunooncology
/in News/by Thomas GabrielczykEvotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Evidence of deliberate climate damage
/in News/by Thomas GabrielczykA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
New polymer can stop biofilm formation
/in News/by Thomas GabrielczykBritish researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Rewind Therapeutics extends Series A financing
/in News/by Thomas GabrielczykWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Henkel buys FDCA from Avantium NV
/in News/by Thomas GabrielczykBioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.